| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
|
J Clin Oncol
|
2004
|
2.09
|
|
2
|
Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
|
J Clin Oncol
|
2006
|
1.56
|
|
3
|
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.47
|
|
4
|
Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.
|
Clin Cancer Res
|
2013
|
1.31
|
|
5
|
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
|
PLoS One
|
2012
|
1.30
|
|
6
|
Cancer caregiving and subjective stress: a multi-site, multi-dimensional analysis.
|
Psychooncology
|
2005
|
1.25
|
|
7
|
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
|
Gastrointest Endosc
|
2012
|
1.19
|
|
8
|
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
|
Surgery
|
2013
|
1.09
|
|
9
|
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.
|
Med Care
|
2009
|
1.02
|
|
10
|
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
|
Clin Cancer Res
|
2004
|
1.00
|
|
11
|
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
|
Int J Cancer
|
2013
|
0.99
|
|
12
|
Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.
|
Cancer Biol Ther
|
2011
|
0.96
|
|
13
|
Inappropriate use of the faecal occult blood test outside of the National Health Service colorectal cancer screening programme.
|
Eur J Gastroenterol Hepatol
|
2012
|
0.95
|
|
14
|
Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare.
|
Med Care
|
2015
|
0.93
|
|
15
|
ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer.
|
J Gastrointest Cancer
|
2012
|
0.91
|
|
16
|
Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.91
|
|
17
|
Composite signet-ring cell/neuroendocrine carcinoma of the stomach with a metastatic neuroendocrine carcinoma component: a better prognosis entity.
|
Diagn Pathol
|
2007
|
0.88
|
|
18
|
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
|
Cancer
|
2011
|
0.88
|
|
19
|
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
|
Gastrointest Endosc
|
2012
|
0.87
|
|
20
|
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.85
|
|
21
|
FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.
|
Cancer Res
|
2013
|
0.85
|
|
22
|
Hospital center effect for laparoscopic colectomy among elderly stage I-III colon cancer patients.
|
Ann Surg
|
2014
|
0.84
|
|
23
|
Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.
|
J Gastrointest Oncol
|
2013
|
0.83
|
|
24
|
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.82
|
|
25
|
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
|
J Am Geriatr Soc
|
2011
|
0.82
|
|
26
|
ACS-NSQIP criteria are associated with APACHE severity and outcomes in critically ill surgical patients.
|
J Am Coll Surg
|
2011
|
0.81
|
|
27
|
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.
|
J Vasc Interv Radiol
|
2012
|
0.80
|
|
28
|
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
|
Pharmacoeconomics
|
2014
|
0.80
|
|
29
|
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.
|
Cancer Med
|
2013
|
0.79
|
|
30
|
Multispecialist Care and Mortality in Hepatocellular Carcinoma.
|
Am J Clin Oncol
|
2015
|
0.78
|
|
31
|
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.
|
Cancer Med
|
2014
|
0.78
|
|
32
|
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival.
|
Value Health
|
2013
|
0.77
|
|
33
|
Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
|
Adv Ther
|
2014
|
0.75
|
|
34
|
Effectiveness of an antimicrobial polymer to decrease contamination of environmental surfaces in the clinical setting.
|
Infect Control Hosp Epidemiol
|
2014
|
0.75
|
|
35
|
Presacral schwannoma diagnosed by EUS-guided FNA.
|
Gastrointest Endosc
|
2007
|
0.75
|